Comparative Pharmacology
Head-to-head clinical analysis: CURRETAB versus NORETHINDRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CURRETAB versus NORETHINDRONE.
CURRETAB vs NORETHINDRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progesterone receptor agonist; induces secretory changes in endometrium, inhibits pituitary gonadotropin secretion, and has anti-estrogenic effects.
Norethindrone is a synthetic progestin that binds to progesterone receptors, suppressing gonadotropin (LH and FSH) release from the pituitary, inhibiting ovulation, and inducing secretory changes in the endometrium. It also has weak androgenic and estrogenic activity.
5 mg orally once daily for 10 consecutive days per cycle, beginning on day 16 of the menstrual cycle.
5 mg orally once daily for 5 days starting on day 5 of menstrual cycle or 0.35 mg orally once daily for contraception.
None Documented
None Documented
Terminal elimination half-life of medroxyprogesterone acetate (MPA) is approximately 12-17 hours (mean ~14 h) for oral administration; with intramuscular depot, half-life extends to ~6-7 weeks due to slow absorption from injection site
Terminal elimination half-life: 5-14 hours (mean 8-10 hours); clinical context: requires once-daily dosing for steady state after ~2 days (5 half-lives).
Primarily renal (60-70% as metabolites, <10% unchanged); biliary/fecal (20-30%)
Renal (30-50% as glucuronide conjugates, 5-10% unchanged), fecal (<10%)
Category C
Category D/X
Progestin
Progestin